이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
ICON 과거 수익 실적
과거 기준 확인 5/6
ICON은 연평균 13%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 증가했으며, 연간 16.8%였습니다. 매출은 연평균 28.4%의 비율로 증가했습니다. ICON의 자기자본이익률은 7.2%이고 순이익률은 8.3%입니다.
주요 정보
16.1%
수익 성장률
2.4%
EPS 성장률
Life Sciences 산업 성장 | 21.5% |
매출 성장률 | 27.4% |
자기자본 수익률 | 7.5% |
순이익 | 8.6% |
최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
An Intrinsic Calculation For ICON Public Limited Company (NASDAQ:ICLR) Suggests It's 28% Undervalued
Aug 10ICON: Deleveraging Complete, Now See 18% CAGR In Valuation To FY'26E (Rating Upgrade)
Jul 13Earnings Tell The Story For ICON Public Limited Company (NASDAQ:ICLR)
Jun 14Here's Why We Think ICON (NASDAQ:ICLR) Is Well Worth Watching
May 30ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet
May 14ICON Public Limited Company Just Recorded A 8.9% EPS Beat: Here's What Analysts Are Forecasting Next
Apr 28What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?
Apr 21ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price
Apr 05ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump
Mar 05With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Feb 07ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?
Feb 01These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Jan 23Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jan 08What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E
Dec 24A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Dec 09With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Nov 08Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Oct 09Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Sep 23Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Sep 05Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?
Aug 03Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jun 30Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Jun 12Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
May 23Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Mar 29Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Mar 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 28%?
Feb 21Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Dec 28These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Dec 10Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 26% Discount?
Nov 22Icon selected by BARDA to conduct anthrax vaccine clinical trial
Oct 06Is ICON Public Limited Company (NASDAQ:ICLR) Potentially Undervalued?
Sep 15ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly
Aug 26Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth
Aug 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?
Aug 01Icon Q2 2022 Earnings Preview
Jul 26ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet
May 11ICON Public Limited Company (NASDAQ:ICLR) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 20수익 및 비용 분석
수익 및 비용 분석
ICON 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 24 | 8,332 | 714 | 758 | 0 |
31 Mar 24 | 8,232 | 683 | 754 | 0 |
31 Dec 23 | 8,120 | 612 | 776 | 0 |
30 Sep 23 | 8,016 | 513 | 808 | 0 |
30 Jun 23 | 7,903 | 510 | 790 | 0 |
31 Mar 23 | 7,818 | 510 | 790 | 0 |
31 Dec 22 | 7,741 | 505 | 783 | 0 |
30 Sep 22 | 7,665 | 464 | 758 | 0 |
30 Jun 22 | 7,588 | 210 | 871 | 0 |
31 Mar 22 | 6,524 | 168 | 771 | 0 |
31 Dec 21 | 5,481 | 153 | 662 | 0 |
30 Sep 21 | 4,356 | 178 | 547 | 0 |
30 Jun 21 | 3,191 | 364 | 350 | 0 |
31 Mar 21 | 2,940 | 338 | 344 | 0 |
31 Dec 20 | 2,797 | 328 | 342 | 0 |
30 Sep 20 | 2,762 | 322 | 343 | 0 |
30 Jun 20 | 2,771 | 324 | 345 | 0 |
31 Mar 20 | 2,846 | 368 | 344 | 0 |
31 Dec 19 | 2,806 | 369 | 333 | 0 |
30 Sep 19 | 2,759 | 362 | 336 | 0 |
30 Jun 19 | 2,704 | 353 | 330 | 0 |
31 Mar 19 | 2,651 | 333 | 328 | 0 |
31 Dec 18 | 2,596 | 323 | 326 | 0 |
30 Sep 18 | 2,372 | 306 | 321 | 0 |
30 Jun 18 | 2,157 | 295 | 320 | 0 |
31 Mar 18 | 1,947 | 288 | 326 | 0 |
31 Dec 17 | 1,758 | 281 | 324 | 0 |
30 Sep 17 | 1,738 | 285 | 331 | 0 |
30 Jun 17 | 1,718 | 274 | 333 | 0 |
31 Mar 17 | 1,698 | 271 | 326 | 0 |
31 Dec 16 | 1,666 | 262 | 326 | 0 |
30 Sep 16 | 1,635 | 251 | 326 | 0 |
30 Jun 16 | 1,609 | 249 | 327 | 0 |
31 Mar 16 | 1,587 | 247 | 328 | 0 |
31 Dec 15 | 1,575 | 240 | 327 | 0 |
30 Sep 15 | 1,562 | 221 | 329 | 0 |
30 Jun 15 | 1,555 | 210 | 331 | 0 |
31 Mar 15 | 1,542 | 192 | 337 | 0 |
31 Dec 14 | 1,503 | 172 | 336 | 0 |
30 Sep 14 | 1,458 | 161 | 330 | 0 |
30 Jun 14 | 1,411 | 138 | 327 | 0 |
31 Mar 14 | 1,369 | 120 | 317 | 0 |
31 Dec 13 | 1,336 | 103 | 314 | 0 |
30 Sep 13 | 1,291 | 90 | 308 | 0 |
양질의 수익: ICLR 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: ICLR 의 현재 순이익 이익률 (8.3%) 작년보다 높습니다 (6.5%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: ICLR 의 수입은 지난 5년 동안 매년 13% 씩 증가했습니다.
성장 가속화: 지난 1년간 ICLR 의 수익 증가율( 33.9% )은 연간 평균( 13% 초과합니다. ).
수익 대 산업: 지난 1년간 ICLR 수익 증가율( 33.9% )은 Life Sciences 업계 -6.5% 초과했습니다.
자기자본 수익률
높은 ROE: ICLR 의 자본 수익률( 7.2% )은 낮음으로 간주됩니다.